Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -29747.89% is 1853% below its 1-year average of -1523.05%, near the low end of its 1-year range (-29747.89%–0.00%).
1853.18% below its 12-month average of -1523.05%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -7615.26%.
NET PROFIT MARGIN
-29747.89%
NET PROFIT MARGIN AVG TTM
-1523.05%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1853.18%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.01%
median of 824 covered companies
CURRENT VS SECTOR MEDIAN
-297478800.00%
vs the sector median at left
Nautilus Biotechnolgy, Inc.
Market Cap
$232.86M
Net Profit Margin
-29747.89%
TTM Avg
-1523.05%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$232.72M
Net Profit Margin
-155582.08%
TTM Avg
-91683.52%
3Y Avg
-62749.43%
5Y Avg
-41832.95%
Market Cap
$231.69M
Net Profit Margin
-8.70%
TTM Avg
-47.52%
3Y Avg
-47.68%
5Y Avg
-98.44%
Market Cap
$229.75M
Net Profit Margin
-912.25%
TTM Avg
-448.06%
3Y Avg
-224.03%
5Y Avg
-224.03%
Market Cap
$236.25M
Net Profit Margin
-13.54%
TTM Avg
-22.79%
3Y Avg
-26.12%
5Y Avg
-61.39%
Market Cap
$236.48M
Net Profit Margin
-183.90%
TTM Avg
-383.83%
3Y Avg
-191.92%
5Y Avg
-127.94%
Market Cap
$236.56M
Net Profit Margin
-4.52%
TTM Avg
-4.68%
3Y Avg
-9.38%
5Y Avg
-10.81%
Market Cap
$236.69M
Net Profit Margin
-5.14%
TTM Avg
33.66%
3Y Avg
36.64%
5Y Avg
40.60%
Market Cap
$228.74M
Net Profit Margin
-26.97%
TTM Avg
-50.02%
3Y Avg
-94.39%
5Y Avg
-87.59%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $232.86M | -29747.89% | -1523.05% | 0.00% | 0.00% |
| InflaRx N.V. (IFRX)vs › | $232.72M | -155582.08% | -91683.52% | -62749.43% | -41832.95% |
| MacroGenics, Inc. (MGNX)vs › | $231.69M | -8.70% | -47.52% | -47.68% | -98.44% |
| BioAge Labs Inc. (BIOA)vs › | $229.75M | -912.25% | -448.06% | -224.03% | -224.03% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.25M | -13.54% | -22.79% | -26.12% | -61.39% |
| Invivyd, Inc. (IVVD)vs › | $236.48M | -183.90% | -383.83% | -191.92% | -127.94% |
| High Tide Inc. (HITI)vs › | $236.56M | -4.52% | -4.68% | -9.38% | -10.81% |
| SIGA Technologies, Inc. (SIGA)vs › | $236.69M | -5.14% | 33.66% | 36.64% | 40.60% |
| Biodesix, Inc. (BDSX)vs › | $228.74M | -26.97% | -50.02% | -94.39% | -87.59% |
| Galectin Therapeutics Inc. (GALT)vs › | $238.40M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
-29747.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -7615.26% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
